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Symptomatic spinal cord involvement in prostate cancer
\  EKE
Abstract
The literature on spinal cord involvement in prostate cancer is reviewed by searching the Medline from 1965 
to 1997 and references in publications on the subject. The objective was to identify the clinical characteristics 
and treatment modalities of the disease.
Prostate cancer is the leading cause of metastatic spinal cord disease in men. The tumour reaches the spinal 
column mainly by the venous route. The frequency of involvement in decreasing order is thoracic spine, 
lumbar spine and cervical spine. The tumour usually exerts compression of the cord from the extradural space. 
However, intradural and intramedullary metastases have devastating effects. The patients have other 
neurological and urological symptoms prior to the onset of paraplegia. But in some, spinal cord compression 
may be the first symptom of prostate cancer. Plain X-rays may suffice in diagnosis but MRI is the single most 
valuable investigation for anatomic definition or localization of spinal cord secondaries. All forms of 
treatment are palliative.
Treatment options, singly or in combination, include hormonal manipulation, radiotherapy and laminectomy 
each often with high dose corticosteroids. Recurrence of symptoms after an initial relief with hormonal 
manipulation signifies escape of the tumour from endocrine control and portends a poor prognosis.
Cent A frJ  Med 2001;47(2):49-53
Introduction
Prostate cancer is a leading cause of cancer death in men, 
second only to lung cancer.1 The highest incidence of 
prostate cancer is recorded in African Caribbeans2 and in 
black Americans in whom the prevalence has been described 
as a public health epidemic.3 Contrary to previous views, 
a high prevalence of prostate cancer has been documented 
in Africans.4-5 The lowest incidence in the world is recorded 
among the Chinese and Asiatics.6
Spinal cord involvement in prostate cancer is a major 
manifestation of advanced disease. The incidence varies 
from one to!2% of patients with prostate cancer.7'10 While
some reports indicate that prostate cancer is the second 
highest spinal metastatic tumour,11 others have identified 
it as the leading source of spinal metastases in men.12’13 The 
literature is reviewed to define the clinical characteristics 
and the treatment modalities of patients with advanced 
prostate cancer and symptomatic spinal cord involvement. 
Pathology.
Prostate cancer is clinically graded from one to five on 
the basis of morphologic abnormalities in the architecture 
of the glandular system, the differentiation of the cancer 
cells, and the definition of the tumour m argin.14 
Histologically, primary prostate cancer is mainly an 
adenocarcinoma which constitutes 95% of prostate cancer.15
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Other malignant primary prostatic diseases include 
rhabdomyosarcoma,16 squamous cell cancer and 
leiomyosarcoma.17 The broad grades range from well- 
differentiated to anaplastic tumours.
All patients with spinal cord compression from prostate 
cancer have multiple bone secondaries at presentation as 
shown by "Technitium scan.18 Metastasis to the spine is 
thought to be by venous spread.19 Most cord secondaries 
occur in the thoracic spine followed by the lumbar spine 
and cervical spines.18,20 In 5% of patients, the secondaries 
are confined to the spinal extradural space. Most commonly 
the vertebral body and the pedicles are affected. The 
tumour thence spreads to the spinal canal.11 Prostatic bone 
secondaries are usually osteoblastic although lytic lesions 
occur.21 The disc space is maintained even when the 
vertebral body collapses. The lesions may be multiple and 
non-contiguous.9,22 Their effect is spinal cord compression. 
Rarely and more devastatingly, intradural and 
intramedullary metastases may occur.23 The spinal cord 
may also be damaged when the metastatic tumour causes 
occlusion of the blood supply to a segment.24 Other 
tumours of the spinal canal to be excluded are lymphoma 
and multiple myeloma 19 as well as primary tumours of the 
lung, kidney and breast.
Presentation.
Early prostate cancer is largely asymptomatic6 and may 
be detected by Prostate Specific Antigen (PSA) estimation, 
especially where screening for the disease is a policy. A 
high proportion of black African patients in the diaspora 
present with advanced disease.3,4 The manifestations of 
advanced disease in prostate cancer include: weight loss, 
bladder outflow obstruction, anaemia, alteration of bowel 
habit, bone pains and the features of spinal cord 
compression. Spinal cord compression presents initially 
with back pain. Compression occurs more in high grade 
tumours.9,25 Spinal cord compression may be the first 
manifestation of prostate cancer.7,8,18 Paraplegia is usually 
preceded by other neurological or urological symptoms or 
rarely, bowel symptoms.18,19 The other neurological 
symptoms include paraparesis, sensory deficits, muscle 
weakness and paraplegia or quadriplegia. In one series of 
patients with neurological symptoms, the frequency of 
these were: pain (75%), sensory symptoms (68%), bladder 
dysfunction (40%), while 46% were bed-ridden.20
The urological symptoms are usually those of the lower 
urinary tract such as retention, frequency, nocturia, urgency, 
haematuria and incontinence. These symptoms often lead 
to the investigation and diagnosis of prostate cancer before 
the onset of paraplegia. Paraplegia, in addition to loss of 
motor function, is usually accompanied by sensory loss. 
The level of neurological symptoms and signs may not 
correspond with the anatomical level of the spinal 
compression.26 Cord compression from prostate cancer 
has been reported to manifest up to 100 months from the 
time of diagnosis of prostate cancer.18,20 
Investigations.
The modalities for early detection of prostate cancer 
include digital rectal examination, PSA estimates, 
transrectal ultrasound scan (TRUS) and biopsy of the
prostate. PSA levels are used to monitor the response or 
relapse of the disease following treatment. Investigations 
of localizing diagnostic importance in spinal cord 
involvement in prostate cancer include:
1. Plain spinal X-rays. These may show (a) typical 
osteoblastic lesions or osteolytic lesions in adjacent 
vertebrae, (b) vertebral body collapse, and (c) the 
involvement of the vertebral body and the pedicles on 
X-ray which shows as the “winking owl sign”.20 The 
radiographic pattern of metastatic prostate cancer is 
often classic enough to make tissue biopsy 
unnecessary for diagnosis.23 However, pathological 
shadows are evident on plain X-rays only when about 
50% of the vertebra has been destroyed.27
2. CT scan (specifically CT myelography). This clearly 
defines the extent of bone involvement and enables 
planning for the route of surgical access to the lesion 
(anterior, posterior or lateral).19,28 It is more sensitive 
in showing bone destruction once the level of the 
lesion has been identified.
3. Magnetic resonance imaging (MR1). This is the most 
valuable single investigation. Its accuracy matches 
that of myelography. It has an advantage over 
myelography in being non-invasive.29 The study 
should cover the entire spine because of the frequency 
of multiple spinal metastases.30,31 It shows the actual 
spinal cord compression. MRI shows bone marrow 
but does not show cortical bone well. Furthermore, 
sclerotic lesions may be missed.
4. Myelography. This is a useful alternative option if 
MRI is not possible from unavailability or from 
difficulty with the positioning of the patient.32 
Observed complications include deterioration of the 
neurological status of the patient.7,33
5. Fine needle biopsy o f identified spinal lesions. This 
is indicated when the primary site in the prostate has 
not been identified.19 It is useful between T5 and L5 
vertebrae when guided by biplanar image intensifier. 
CT guided needle biopsy for all levels is an alternative. 
Reported complications include haemothorax, 
pneumothorax, haemorrhage and neurologic 
deterioration.23
6 Radionuclide scanning. Radionuclide whole-body 
bone scintigraphy is universally preferred for defecting 
bony involvement in prostate cancer34 and should be 
employed in the evaluation of patients suspected to 
have spinal cord compression from prostate cancer. 
Treatment.
Spinal cord involvement in prostate cancer has been 
described as an oncologic emergency.32 Urgent treatment 
is essential to prevent irreversible cord damage19,32,35 and 
requires early diagnosis.36,37 The immediate aim of treatment 
is to decompress the spinal cord and to preserve the 
stability of the spine. The treatment modalities are hormonal 
manipulation,38,39 radiotherapy40'42 and laminectomy19,23,43 
either singly or in combination. High dose corticosteroids 
are added to any of these modalities.18,20 Hormonal 
manipulation involves androgen deprivation. This may be
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achieved by the use of drugs or by orchidectomy. The 
drugs such as the antiandrogens flutamide and bicalutamide 
(Casodex) or the LH-RH Analog goserelin (Zoladex) are 
rarely available and are often unaffordable to most patients 
in developing countries. Orchidectomy is effective although 
usually only temporarily so. Urgent orchidedtomy with 
high dose intravenous steroids is effective in some 
individuals with paraplegia.18 32
Local radiotherapy by external beam irradiation provides 
prompt and durable relief of compression at a specific 
spinal lesion site. Systemic radiation may be applied in 
multiple spinal lesions.41
The most rapid effective treatment of spinal cord 
compression is laminectomy during which a compressing 
tumour or collapsed vertebra may be removed.19 Such 
treatment should take into account the expected life 
expectancy of thepatient. Terminally ill patients are unlikely 
to benefit from laminectomy. If a combination of tumour, 
bone, and disc compresses the spinal cord, laminectomy is 
the only remedy with hope of successful palliation.23 
Indications for laminectomy in spinal cord compression 
from prostate cancer include severe myelopathy, spinal 
instability and rapid neurological deterioration during or 
after radiotherapy.10 However, laminectomy is ineffective 
in the presence of vertebral body disease and may worsen 
the neurological status as well as the stability of the 
spine.19,36 Other complications include failure of treatment 
in the short or long term with recurrence of compression.18'44
There is no clearly established superiority of laminectomy 
with radiotherapy over radiotherapy alone.43 When 
available, combined radiotherapy and androgen blockade 
may precede laminectomy.20 High dose corticosteroids 
(Dexamethasone) are used to reduce spinal cord oedema 
resulting from the initial cause of compression and from 
tumour infarction from hormonal and radiotherapeutic 
treatments.1032
Inhibitors of bone turnover like mithramycin used in 
Paget’s disease of bone have been found effective in 
prostatic metastatic bone disease.45
The results of treatment of spinal cord involvement in 
prostate cancer range from full recovery through partial 
relief of motor and/or sensory deficits35 to total failure in 
paraplegic patients.18 36 Relief in paraplegic patients has 
been sustained for up to two years with hormonal treatment 
alone.38 Survival up to eight years following combination 
treatment for an intradural lesion has been recorded.9 
Spinal cord compression may relapse after an initial 
response to treatment.18,44,46 Such recurrent compression 
may be at a different leve1,8
Discussion
Paraplegia is a serious complication of metastatic stage D2 
adenocarcinoma of the prostate.20 The diagnosis is not 
difficult to make. Localization of the compression site by 
MRI or myelography is essential for such treatment 
modalities as local radiotherapy and laminectomy. 
Distressingly, apart from plain X-rays, the investigations
essential in the evaluation of these patients are not readily 
accessible to patients in developing countries.
All forms of treatment of spinal cord involvement in 
prostate cancer can only be palliative.10 The prognosis in 
spinal cord invasion by prostate cancer is poor even with 
the combination therapies.18 While local spread of tumour 
is associated with high morbidity, distant metastasis have 
worse prognosis at all ages. The poorer the differentiation, 
the worse the prognosis.7'9'1 1,47,48 Several prognostic factors 
have been identified by various authors but these do not 
apply universally to all patients. It has been suggested from 
one study that no patient who was paraplegic prior to 
treatment regained full function.7 Also recently, it was 
concluded that pretreatment ambulatory function is the 
main determinant of post treatment gait function.49 This 
point was refuted in other studies in which some 
quadriplegic and paraplegic patients regained full powers 
in the limbs after bilateral subcapsular orchidectomy.31,46 
Treatment at an early stage of prostate cancer with hormonal 
manipulation is expected to reduce the occurrence of 
serious complications such as spinal cord involvement.50 
Patients with spinal cord compression who improve with 
treatment have a longer survival than those who fail to 
respond.
Careful selection of patients for laminectomy is essential. 
Laminectomy as a palliative procedure is a major 
operation.18 However, bilateral subcapsular orchiectomy 
(BSO) for hormonal manipulation is a simple procedure. 
Moreover, as the spinal lesions may be multiple and non­
contiguous, BSO may be preferred to laminectomy.
Recurrence of spinal cord compression after an initial 
successful endocrine treatment connotes escape of prostate 
cancer from endocrine control and is associated with a 
poor prognosis.46,51 An effort to explain this escape has 
been made by Isaacs.52 Recent studies have demonstrated 
that the normal prostate is heterogenous, composed of 
stem cell units hierarchically containing androgen- 
independent stem cells, androgen-sensitive amplifying 
cells, and androgen-dependent transit epithelial cells. 
Cancer cells arisingfrom each of these subsets may display 
' a characteristic response with respect to hormonal 
manipulations. Although patients with prostate cancer 
bony metastasis (D2 disease) respond well to first-line 
hormonal therapy with orchiectomy, antiandrogens or LH- 
RH analogs, hormone refractory metastatic disease (D3 
disease) will ultimately develop in most patients.41
Conclusion
In view of the unpredictable course of advanced prostate 
cancer as in spinal cord involvement, it is considered 
worthwhile to offer such patients hormonal treatment 
irrespective of the delay in presentation. It has been 
suggested that many patients with prostate cancer die with 
the disease but not from it.53,54 Until a reliable cure is found 
for this epidemic, most patients with spinal cord 
involvement in prostate cancer will die from  the disease.
Cent Afr J Med 2001;47(2) 51
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